AntibioticDB

Teixobactin

Cell-wall synthesis inhibitor (lipid II inhibitor)

Novobiotic pharmaceuticals, USA (northeastern)

2015

Highest development stage: Preclinical
Development active
Gram-positive activity
Propensity to select resistant bacteria
Mechanism of Action/Target pathogen: Staphylococcus aureus
Additional information: Natural compound
GtoPDB link: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10972
Citation (1): https://www.ncbi.nlm.nih.gov/pubmed/25561178
Citation (2): https://msystems.asm.org/content/5/3/e00077-20
Compound/Drug Structure: https://pubchem.ncbi.nlm.nih.gov/compound/86341926